<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655863</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322_301</org_study_id>
    <secondary_id>2007-000486-38</secondary_id>
    <secondary_id>U1111-1113-2081</secondary_id>
    <secondary_id>NL22649.029.08</secondary_id>
    <nct_id>NCT00655863</nct_id>
  </id_info>
  <brief_title>Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.</brief_title>
  <official_title>Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Alogliptin, once daily (QD), taken by
      itself and with pioglitazone on postprandial lipid measures in type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SYR-322 (alogliptin) is a selective, orally available inhibitor of dipeptidyl peptidase IV
      being developed as a treatment for type 2 diabetes mellitus. Dipeptidyl peptidase IV is the
      primary enzyme involved in the in vivo degradation of at least 2 peptide hormones released in
      response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent
      insulinotropic peptide.

      Pioglitazone HCl (ACTOSÂ®) is a thiazolidinedione developed by Takeda Chemical Industries,
      Ltd. (Osaka, Japan). Pioglitazone HCl depends on the presence of insulin for its mechanism of
      action.

      This study will assess the effects of alogliptin and alogliptin coadministered with
      pioglitazone HCl on postprandial lipid and lipoprotein metabolism in participants with type 2
      diabetes. Individuals who participate in this study will be required to commit to a screening
      visit and up to 6 additional visits at the study center. Study participation is anticipated
      to be about 20 weeks (or approximately 5 months). Multiple procedures will occur at each
      visit which may include fasting, blood collection, urine collection, physical examinations
      and electrocardiograms. At 3 of the visits a meal will be served that must be eaten within 10
      minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.</measure>
    <time_frame>Baseline and Week 16.</time_frame>
    <description>The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.</measure>
    <time_frame>Baseline and Week 4.</time_frame>
    <description>The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>Postprandial changes over time at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Changes Over Time From Baseline for Glucose</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>Postprandial changes over time at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Changes Over Time From Baseline for Insulin</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>Postprandial changes over time at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Changes Over Time From Baseline for Glucagon</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>Postprandial changes over time at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin</measure>
    <time_frame>Baseline, Week 8 and Week 16.</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline, Week 4, Week 8 and Week 16.</time_frame>
    <description>The change in fasting plasma glucose collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial C-Peptide</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in postprandial C-peptide collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postprandial Proinsulin</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in postprandial proinsulin collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in hs-CRP collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in adiponectin collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in VCAM collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in ICAM collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in e-Selectin</measure>
    <time_frame>Baseline, Week 4 and Week 16.</time_frame>
    <description>The change in e-Selectin collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Endothelial Function Through Pulse Wave Tonometry</measure>
    <time_frame>Baseline and Week 16.</time_frame>
    <description>Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin and Pioglitazone</intervention_name>
    <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
    <arm_group_label>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</arm_group_label>
    <other_name>alogliptin</other_name>
    <other_name>SYR110322</other_name>
    <other_name>Actos</other_name>
    <other_name>AD-4833</other_name>
    <other_name>SYR-322</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
    <arm_group_label>Alogliptin 25 mg QD</arm_group_label>
    <other_name>SYR110322</other_name>
    <other_name>SYR-322</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
    <other_name>Actos</other_name>
    <other_name>AD-4833</other_name>
    <other_name>SYR-322</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Diagnosis of type 2 diabetes

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Either failed treatment with diet and exercise for 3 months prior to Screening or has
             been receiving a stable dose of metformin, sulfonylurea, nateglinide, or repaglinide
             for more than 3 months prior to Screening.

          -  Inadequate glycemic control as defined by glycosylated hemoglobin concentration
             between 6.5 and 9.0%, inclusive.

          -  Fasting plasma glucose less than 13.3 mmol per L.

          -  Fasting serum triglyceride level of 1.7 to 5.0 mmol per L, inclusive.

          -  Has not been receiving any lipid-lowering therapy within 3 months prior to Screening
             or on a stable statin and/or ezetimibe therapy (same drug and dose) for at least 3
             months.

          -  Body mass index greater than 23 kg/m2 and less than 45 kg/m2.

          -  If has regular use of other, non-excluded medications, must be on a stable dose for at
             least 4 weeks prior to Screening. Use of as needed prescription medications and
             over-the-counter medications is allowed at the discretion of the investigator.

          -  Is to be Apolipoprotein E 3/3 or Apolipoprotein E 3/4 phenotype positive prior to
             baseline.

        Exclusion Criteria

          -  History of type 1 diabetes.

          -  History of drug abuse (defined as illicit drug use) or a history of alcohol abuse
             (defined as regular or daily consumption of more than 4 alcoholic drinks per day)
             within the past 2 years.

          -  Diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of
             greater than 160 mm Hg.

          -  History of cancer, other than basal cell carcinoma, that has not been in remission for
             at least 5 years prior to the first dose of study medication.

          -  Hemoglobin less than 120 g per L for males and less than100 g per L for females.

          -  Alanine transaminase level greater than 2.5 times the upper limit of normal, active
             liver disease, or jaundice.

          -  Serum creatinine level greater than 133 Î¼mol per L.

          -  Fasting total cholesterol greater than 6.5 mmol per L.

          -  New York Heart Association heart failure of any Class (I-IV) regardless of therapy.

          -  History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or
             myocardial infarction within 6 months prior to Screening.

          -  History of acute metabolic diabetic complications.

          -  History of any hemoglobinopathy that may affect determination of glycosylated
             hemoglobin.

          -  History of infection with human immunodeficiency virus.

          -  History of diabetic gastro paresis.

          -  History of gastric bypass surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOS Package Insert.</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Eliasson B, MÃ¶ller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR, Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012 Apr;55(4):915-25. doi: 10.1007/s00125-011-2447-3. Epub 2012 Jan 12.</citation>
    <PMID>22237690</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>February 17, 2013</results_first_submitted>
  <results_first_submitted_qc>May 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2013</results_first_posted>
  <last_update_submitted>May 23, 2013</last_update_submitted>
  <last_update_submitted_qc>May 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Lipoatrophic; Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled at 2 investigative sites in The Netherlands and Sweden from 16 July 2007 to 17 December 2009.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of type 2 diabetes mellitus were enrolled in one of three, once-daily (QD) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo QD</title>
          <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Alogliptin 25 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo QD</title>
          <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Alogliptin 25 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="6.23"/>
                    <measurement group_id="B2" value="58.7" spread="6.47"/>
                    <measurement group_id="B3" value="59.1" spread="6.94"/>
                    <measurement group_id="B4" value="59.0" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>White</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.83" spread="11.989"/>
                    <measurement group_id="B2" value="93.68" spread="10.816"/>
                    <measurement group_id="B3" value="93.05" spread="13.160"/>
                    <measurement group_id="B4" value="96.24" spread="12.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.3" spread="6.74"/>
                    <measurement group_id="B2" value="173.9" spread="8.17"/>
                    <measurement group_id="B3" value="172.8" spread="10.97"/>
                    <measurement group_id="B4" value="175.0" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.12" spread="3.997"/>
                    <measurement group_id="B2" value="31.09" spread="4.196"/>
                    <measurement group_id="B3" value="31.15" spread="3.503"/>
                    <measurement group_id="B4" value="31.46" spread="3.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.55" spread="3.243"/>
                    <measurement group_id="B2" value="6.40" spread="3.622"/>
                    <measurement group_id="B3" value="5.03" spread="3.791"/>
                    <measurement group_id="B4" value="5.69" spread="3.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.</title>
        <description>The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline.</description>
        <time_frame>Baseline and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.</title>
          <description>The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg.h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.728" spread="48.2481"/>
                    <measurement group_id="O2" value="-346.957" spread="47.2251"/>
                    <measurement group_id="O3" value="-293.439" spread="51.1271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis that there was no difference between Alogliptin 25 mg QD and placebo groups was tested at a 2-sided 0.05 significance level. The ANCOVA model used for the change in postprandial incremental area the curver for total triglycerides includes treatment and statin use as fixed effects and baseline AUC(0-8h) for total triglycerides as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value and confidence interval presented without multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-307.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-443.168</ci_lower_limit>
            <ci_upper_limit>-171.290</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis that there was no difference between Alogliptin 25 mg QD + Pioglitazone 30 mg QD and placebo QD groups was tested at a 2-sided 0.05 significance level. The ANCOVA model used for the change in postprandial incremental area the curve for total triglycerides includes treatment and statin use as fixed effects and baseline AUC(0-8h) for total triglycerides as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value and confidence interval presented without multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-253.711</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-394.161</ci_lower_limit>
            <ci_upper_limit>-113.262</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.</title>
        <description>The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline.</description>
        <time_frame>Baseline and Week 4.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.</title>
          <description>The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg.h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.291" spread="61.1286"/>
                    <measurement group_id="O2" value="-288.490" spread="65.4530"/>
                    <measurement group_id="O3" value="-279.116" spread="68.4947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.</title>
        <description>The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.</title>
          <description>The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg.h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VLDL triglycerides Week 4 (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.488" spread="35.4108"/>
                    <measurement group_id="O2" value="-119.009" spread="37.0255"/>
                    <measurement group_id="O3" value="-98.758" spread="38.9818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL triglycerides Week 16 (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.194" spread="29.4896"/>
                    <measurement group_id="O2" value="-130.459" spread="28.2397"/>
                    <measurement group_id="O3" value="-85.709" spread="30.7867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL cholesterol Week 4 (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.914" spread="4.3110"/>
                    <measurement group_id="O2" value="-14.760" spread="4.4843"/>
                    <measurement group_id="O3" value="-10.760" spread="4.7065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL cholesterol Week 16 (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.561" spread="3.4790"/>
                    <measurement group_id="O2" value="-16.365" spread="3.3125"/>
                    <measurement group_id="O3" value="-8.747" spread="3.5984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL 2 triglycerides Week 4 (n=23; n=20; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.221" spread="7.8102"/>
                    <measurement group_id="O2" value="-17.960" spread="8.3710"/>
                    <measurement group_id="O3" value="-8.687" spread="8.6678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL 2 triglycerides Week 16 (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.280" spread="3.4497"/>
                    <measurement group_id="O2" value="-18.986" spread="3.3104"/>
                    <measurement group_id="O3" value="-23.061" spread="3.6369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL 2 cholesterol Week 4 (n=23; n=20; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.396" spread="0.8474"/>
                    <measurement group_id="O2" value="-0.709" spread="0.9059"/>
                    <measurement group_id="O3" value="-1.073" spread="0.9345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL 2 cholesterol Week 16 (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.190" spread="0.7833"/>
                    <measurement group_id="O2" value="-1.445" spread="0.7506"/>
                    <measurement group_id="O3" value="-1.232" spread="0.8217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron triglycerides Week 4 (n=23; n=21; n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.617" spread="26.1603"/>
                    <measurement group_id="O2" value="-115.093" spread="27.4280"/>
                    <measurement group_id="O3" value="-108.036" spread="28.6857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron triglycerides Week 16(n=23;n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.577" spread="15.2943"/>
                    <measurement group_id="O2" value="-136.626" spread="14.6683"/>
                    <measurement group_id="O3" value="-129.991" spread="15.9053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron cholesterol Week 4 (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="1.1845"/>
                    <measurement group_id="O2" value="-4.474" spread="1.2425"/>
                    <measurement group_id="O3" value="-3.628" spread="1.3039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron cholesterol Week 16 (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.431" spread="0.6001"/>
                    <measurement group_id="O2" value="-5.566" spread="0.5769"/>
                    <measurement group_id="O3" value="-4.289" spread="0.6265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL triglycerides Week 4 (n=22; n=18; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.667" spread="12.9991"/>
                    <measurement group_id="O2" value="-6.771" spread="14.3964"/>
                    <measurement group_id="O3" value="-4.410" spread="14.9182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL triglycerides Week 16 (n=22; n=23; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.313" spread="2.9265"/>
                    <measurement group_id="O2" value="-4.045" spread="2.8759"/>
                    <measurement group_id="O3" value="-4.533" spread="3.1885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL cholesterol Week 4 (n=22; n=18; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.473" spread="1.5215"/>
                    <measurement group_id="O2" value="-0.808" spread="1.6835"/>
                    <measurement group_id="O3" value="0.195" spread="1.7328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL cholesterol Week 16 (n=22; n=23; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.171" spread="0.6006"/>
                    <measurement group_id="O2" value="0.249" spread="0.5893"/>
                    <measurement group_id="O3" value="0.609" spread="0.6499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.</title>
        <description>Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.</title>
          <description>Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg.h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VLDL apo B-48 Week 4 (n=19; n=12; n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.2902"/>
                    <measurement group_id="O2" value="-0.491" spread="0.3572"/>
                    <measurement group_id="O3" value="-0.312" spread="0.3180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL apo B-48 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" spread="0.1956"/>
                    <measurement group_id="O2" value="-0.654" spread="0.2077"/>
                    <measurement group_id="O3" value="-0.266" spread="0.2044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL apo B 100 Week 4 (n=19; n=12; n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568" spread="2.2981"/>
                    <measurement group_id="O2" value="-2.670" spread="2.8906"/>
                    <measurement group_id="O3" value="-2.977" spread="2.5811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL apo B 100 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.453" spread="1.8388"/>
                    <measurement group_id="O2" value="-6.967" spread="2.0109"/>
                    <measurement group_id="O3" value="-3.265" spread="2.0025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL2 apo B-48 Week 4 (n=19; n=12; n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.075" spread="0.0776"/>
                    <measurement group_id="O2" value="-0.101" spread="0.0969"/>
                    <measurement group_id="O3" value="-0.022" spread="0.0870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL2 apo B-48 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079" spread="0.0674"/>
                    <measurement group_id="O2" value="-0.175" spread="0.0732"/>
                    <measurement group_id="O3" value="0.002" spread="0.0737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL2 apo B 100 Week 4 (n=19; n=12; n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.464" spread="1.1846"/>
                    <measurement group_id="O2" value="0.507" spread="1.4982"/>
                    <measurement group_id="O3" value="-0.781" spread="1.33287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL2 apo B 100 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.155" spread="0.7985"/>
                    <measurement group_id="O2" value="-2.049" spread="0.8732"/>
                    <measurement group_id="O3" value="-1.793" spread="0.8707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron apo B-48 Week 4 (n=19; n=12; n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.0236"/>
                    <measurement group_id="O2" value="-0.097" spread="0.0302"/>
                    <measurement group_id="O3" value="-0.071" spread="0.0272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron apo B-48 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.0180"/>
                    <measurement group_id="O2" value="-0.113" spread="0.0197"/>
                    <measurement group_id="O3" value="-0.084" spread="0.0191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron apo B 100 Week 4(n=19; n=12; n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.123" spread="0.0825"/>
                    <measurement group_id="O2" value="-0.417" spread="0.1041"/>
                    <measurement group_id="O3" value="-0.389" spread="0.0960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chylomicron apo B 100 Week 16 (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.120" spread="0.0544"/>
                    <measurement group_id="O2" value="-0.419" spread="0.0594"/>
                    <measurement group_id="O3" value="-0.409" spread="0.0590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL apo B-48 Week 4 (n=18; n=10; n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.1254"/>
                    <measurement group_id="O2" value="-0.247" spread="0.1707"/>
                    <measurement group_id="O3" value="-0.223" spread="0.1476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL apo B-48 Week 16 (n=18; n=14; n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.1368"/>
                    <measurement group_id="O2" value="-0.188" spread="0.1580"/>
                    <measurement group_id="O3" value="0.021" spread="0.1561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL apo B 100 Week 4 (n=18; n=10; n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" spread="3.3778"/>
                    <measurement group_id="O2" value="-2.029" spread="4.5494"/>
                    <measurement group_id="O3" value="-2.769" spread="3.8565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL apo B 100 Week 16 (n=18; n=14; n=14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.181" spread="3.4923"/>
                    <measurement group_id="O2" value="-2.876" spread="3.9944"/>
                    <measurement group_id="O3" value="0.073" spread="3.8906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRR lipoproteins Week 4 (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.147" spread="5.6739"/>
                    <measurement group_id="O2" value="-1.071" spread="6.0930"/>
                    <measurement group_id="O3" value="-5.673" spread="6.4428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRR lipoproteins Week 16 (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.818" spread="3.1250"/>
                    <measurement group_id="O2" value="-12.719" spread="3.0884"/>
                    <measurement group_id="O3" value="-7.853" spread="3.3658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)</title>
        <description>Postprandial changes over time at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)</title>
          <description>Postprandial changes over time at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=20; n=17; n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.167"/>
                    <measurement group_id="O2" value="-5.48" spread="1.249"/>
                    <measurement group_id="O3" value="-4.88" spread="1.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=21; n=17; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.524"/>
                    <measurement group_id="O2" value="-2.93" spread="1.702"/>
                    <measurement group_id="O3" value="-6.41" spread="1.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=21; n=17; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.619"/>
                    <measurement group_id="O2" value="-2.08" spread="1.789"/>
                    <measurement group_id="O3" value="-3.61" spread="1.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=21; n=17; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.823"/>
                    <measurement group_id="O2" value="2.86" spread="2.027"/>
                    <measurement group_id="O3" value="-0.84" spread="2.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=19; n=16; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="0.955"/>
                    <measurement group_id="O2" value="-0.38" spread="1.039"/>
                    <measurement group_id="O3" value="-0.72" spread="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=21 ; n=20; n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.304"/>
                    <measurement group_id="O2" value="-4.10" spread="1.326"/>
                    <measurement group_id="O3" value="-3.63" spread="1.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=21; n=21; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.59" spread="1.451"/>
                    <measurement group_id="O2" value="-3.75" spread="1.457"/>
                    <measurement group_id="O3" value="-3.75" spread="1.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=21; n=21; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="1.206"/>
                    <measurement group_id="O2" value="-2.25" spread="1.202"/>
                    <measurement group_id="O3" value="-3.17" spread="1.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=21; n=21; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="1.263"/>
                    <measurement group_id="O2" value="-1.88" spread="1.271"/>
                    <measurement group_id="O3" value="-1.83" spread="1.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=21; n=21; n=17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.820"/>
                    <measurement group_id="O2" value="0.03" spread="0.819"/>
                    <measurement group_id="O3" value="-1.48" spread="0.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Changes Over Time From Baseline for Glucose</title>
        <description>Postprandial changes over time at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Changes Over Time From Baseline for Glucose</title>
          <description>Postprandial changes over time at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.957" spread="5.3970"/>
                    <measurement group_id="O2" value="-35.065" spread="5.7617"/>
                    <measurement group_id="O3" value="-65.905" spread="6.0315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.049" spread="5.9932"/>
                    <measurement group_id="O2" value="-24.721" spread="6.2299"/>
                    <measurement group_id="O3" value="-67.718" spread="6.5647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=24; n=21; n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.200" spread="6.3047"/>
                    <measurement group_id="O2" value="-19.367" spread="6.7356"/>
                    <measurement group_id="O3" value="-54.345" spread="7.2106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.930" spread="5.3775"/>
                    <measurement group_id="O2" value="-13.907" spread="5.6699"/>
                    <measurement group_id="O3" value="-48.643" spread="6.0151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=22; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="4.1120"/>
                    <measurement group_id="O2" value="-6.077" spread="4.2043"/>
                    <measurement group_id="O3" value="-27.856" spread="4.3961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.867" spread="8.1356"/>
                    <measurement group_id="O2" value="-36.189" spread="7.9793"/>
                    <measurement group_id="O3" value="-58.168" spread="8.6585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=23; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.324" spread="8.6572"/>
                    <measurement group_id="O2" value="-29.745" spread="8.2830"/>
                    <measurement group_id="O3" value="-61.899" spread="9.0248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=24; n=25; n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.379" spread="7.8017"/>
                    <measurement group_id="O2" value="-16.996" spread="7.6465"/>
                    <measurement group_id="O3" value="-51.891" spread="8.4838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.849" spread="7.3084"/>
                    <measurement group_id="O2" value="-12.517" spread="7.1054"/>
                    <measurement group_id="O3" value="-41.943" spread="7.7396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.266" spread="5.0112"/>
                    <measurement group_id="O2" value="-5.737" spread="4.9335"/>
                    <measurement group_id="O3" value="-19.381" spread="5.3350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Changes Over Time From Baseline for Insulin</title>
        <description>Postprandial changes over time at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Changes Over Time From Baseline for Insulin</title>
          <description>Postprandial changes over time at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=24; n=21; n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.047" spread="3.5562"/>
                    <measurement group_id="O2" value="-5.867" spread="3.7749"/>
                    <measurement group_id="O3" value="-18.287" spread="4.0906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.405" spread="6.3051"/>
                    <measurement group_id="O2" value="3.161" spread="6.7294"/>
                    <measurement group_id="O3" value="-28.700" spread="7.0572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.637" spread="5.2789"/>
                    <measurement group_id="O2" value="0.652" spread="5.6125"/>
                    <measurement group_id="O3" value="-18.842" spread="5.9301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.999" spread="3.5652"/>
                    <measurement group_id="O2" value="5.092" spread="3.8075"/>
                    <measurement group_id="O3" value="-12.891" spread="4.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.174" spread="1.0270"/>
                    <measurement group_id="O2" value="2.685" spread="1.0772"/>
                    <measurement group_id="O3" value="-6.000" spread="1.1301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.896" spread="4.8993"/>
                    <measurement group_id="O2" value="-14.368" spread="4.7784"/>
                    <measurement group_id="O3" value="-12.162" spread="5.2052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.258" spread="6.5119"/>
                    <measurement group_id="O2" value="-9.528" spread="6.4000"/>
                    <measurement group_id="O3" value="-24.777" spread="6.9371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.447" spread="4.8889"/>
                    <measurement group_id="O2" value="-9.848" spread="4.7800"/>
                    <measurement group_id="O3" value="-23.025" spread="5.2049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.405" spread="4.5090"/>
                    <measurement group_id="O2" value="-4.753" spread="4.4158"/>
                    <measurement group_id="O3" value="-19.329" spread="4.8159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.495" spread="1.2847"/>
                    <measurement group_id="O2" value="3.163" spread="1.2637"/>
                    <measurement group_id="O3" value="-6.107" spread="1.3728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Changes Over Time From Baseline for Glucagon</title>
        <description>Postprandial changes over time at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Changes Over Time From Baseline for Glucagon</title>
          <description>Postprandial changes over time at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.222" spread="3.7636"/>
                    <measurement group_id="O2" value="-14.639" spread="4.0619"/>
                    <measurement group_id="O3" value="-17.704" spread="4.2418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.730" spread="3.3262"/>
                    <measurement group_id="O2" value="-17.015" spread="3.5627"/>
                    <measurement group_id="O3" value="-22.081" spread="3.7541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.637" spread="3.7141"/>
                    <measurement group_id="O2" value="-13.200" spread="3.9753"/>
                    <measurement group_id="O3" value="-15.987" spread="4.2015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=24; n=20; n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.021" spread="4.1496"/>
                    <measurement group_id="O2" value="-4.679" spread="4.5627"/>
                    <measurement group_id="O3" value="-8.860" spread="4.7910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=22; n=20; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.081" spread="3.5000"/>
                    <measurement group_id="O2" value="-3.789" spread="3.6665"/>
                    <measurement group_id="O3" value="-5.150" spread="3.7592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.318" spread="3.1819"/>
                    <measurement group_id="O2" value="-16.955" spread="3.1477"/>
                    <measurement group_id="O3" value="-17.462" spread="3.4144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.047" spread="3.4159"/>
                    <measurement group_id="O2" value="-20.949" spread="3.3556"/>
                    <measurement group_id="O3" value="-20.662" spread="3.6653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.842" spread="3.4670"/>
                    <measurement group_id="O2" value="-13.602" spread="3.4048"/>
                    <measurement group_id="O3" value="10.84" spread="3.7260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=24; n=24; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.801" spread="3.1830"/>
                    <measurement group_id="O2" value="-8.577" spread="3.1873"/>
                    <measurement group_id="O3" value="-10.326" spread="3.4011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.917" spread="2.5383"/>
                    <measurement group_id="O2" value="-5.818" spread="2.4876"/>
                    <measurement group_id="O3" value="-9.332" spread="2.7108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 8 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8: fasting (n=23; n=24; n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.084"/>
                    <measurement group_id="O2" value="-0.55" spread="0.083"/>
                    <measurement group_id="O3" value="-1.01" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24;n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.131"/>
                    <measurement group_id="O2" value="-0.39" spread="0.129"/>
                    <measurement group_id="O3" value="-0.95" spread="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose</title>
        <description>The change in fasting plasma glucose collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4, Week 8 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose</title>
          <description>The change in fasting plasma glucose collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=24; n=20; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.141" spread="3.0027"/>
                    <measurement group_id="O2" value="-20.669" spread="3.3024"/>
                    <measurement group_id="O3" value="-38.826" spread="3.3890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.864" spread="5.3254"/>
                    <measurement group_id="O2" value="-16.293" spread="5.2451"/>
                    <measurement group_id="O3" value="-38.242" spread="5.7203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.869" spread="6.4897"/>
                    <measurement group_id="O2" value="-17.052" spread="6.3918"/>
                    <measurement group_id="O3" value="-38.481" spread="6.9709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial C-Peptide</title>
        <description>The change in postprandial C-peptide collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial C-Peptide</title>
          <description>The change in postprandial C-peptide collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.2597"/>
                    <measurement group_id="O2" value="-0.300" spread="0.2775"/>
                    <measurement group_id="O3" value="-1.199" spread="0.2921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.311" spread="0.3789"/>
                    <measurement group_id="O2" value="-0.011" spread="0.4052"/>
                    <measurement group_id="O3" value="-1.379" spread="0.4262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.376" spread="0.4386"/>
                    <measurement group_id="O2" value="0.116" spread="0.4684"/>
                    <measurement group_id="O3" value="-1.230" spread="0.4933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.256" spread="0.3674"/>
                    <measurement group_id="O2" value="0.393" spread="0.3926"/>
                    <measurement group_id="O3" value="-1.173" spread="0.4140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=23; n=20; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.063" spread="0.1530"/>
                    <measurement group_id="O2" value="0.421" spread="0.1643"/>
                    <measurement group_id="O3" value="-0.911" spread="0.1699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.176" spread="0.3474"/>
                    <measurement group_id="O2" value="-1.021" spread="0.3405"/>
                    <measurement group_id="O3" value="-0.646" spread="0.3712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.4337"/>
                    <measurement group_id="O2" value="-1.006" spread="0.4259"/>
                    <measurement group_id="O3" value="-1.055" spread="0.4638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.492" spread="0.4570"/>
                    <measurement group_id="O2" value="-0.712" spread="0.4478"/>
                    <measurement group_id="O3" value="-1.269" spread="0.4882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" spread="0.4042"/>
                    <measurement group_id="O2" value="-0.068" spread="0.3961"/>
                    <measurement group_id="O3" value="-1.515" spread="0.4323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=24; n=24; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.2042"/>
                    <measurement group_id="O2" value="0.588" spread="0.2047"/>
                    <measurement group_id="O3" value="-0.761" spread="0.2194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postprandial Proinsulin</title>
        <description>The change in postprandial proinsulin collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postprandial Proinsulin</title>
          <description>The change in postprandial proinsulin collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 1 hour postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.555" spread="3.9248"/>
                    <measurement group_id="O2" value="-13.024" spread="4.2068"/>
                    <measurement group_id="O3" value="-41.192" spread="4.4562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 2 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.208" spread="5.5216"/>
                    <measurement group_id="O2" value="-12.568" spread="5.9505"/>
                    <measurement group_id="O3" value="-56.478" spread="6.3185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 3 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.735" spread="5.9547"/>
                    <measurement group_id="O2" value="-12.987" spread="6.4485"/>
                    <measurement group_id="O3" value="-59.573" spread="6.8034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 4 hours postprandial (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.496" spread="5.9756"/>
                    <measurement group_id="O2" value="-6.848" spread="6.4875"/>
                    <measurement group_id="O3" value="-52.649" spread="6.8526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: 8 hours postprandial (n=23; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.082" spread="4.3735"/>
                    <measurement group_id="O2" value="-5.561" spread="4.6395"/>
                    <measurement group_id="O3" value="-35.159" spread="4.9287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 1 hour postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.081" spread="5.3253"/>
                    <measurement group_id="O2" value="-22.812" spread="5.2274"/>
                    <measurement group_id="O3" value="-30.658" spread="5.7287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.336" spread="6.3373"/>
                    <measurement group_id="O2" value="-29.930" spread="6.2396"/>
                    <measurement group_id="O3" value="-45.487" spread="6.8516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 3 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.863" spread="6.2769"/>
                    <measurement group_id="O2" value="-27.768" spread="6.2041"/>
                    <measurement group_id="O3" value="-50.058" spread="6.7783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 4 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.671" spread="5.7153"/>
                    <measurement group_id="O2" value="-21.862" spread="5.6549"/>
                    <measurement group_id="O3" value="-48.757" spread="6.1834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 8 hours postprandial (n=24; n=25; n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.935" spread="5.2859"/>
                    <measurement group_id="O2" value="-6.898" spread="5.2307"/>
                    <measurement group_id="O3" value="-28.776" spread="5.7372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)</title>
        <description>The change in hs-CRP collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)</title>
          <description>The change in hs-CRP collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 5 minutes prior to meal (n=24; n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.514" spread="1.0846"/>
                    <measurement group_id="O2" value="0.631" spread="1.1693"/>
                    <measurement group_id="O3" value="0.155" spread="1.2269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24; n=25;n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.338" spread="2.6070"/>
                    <measurement group_id="O2" value="-0.402" spread="2.5683"/>
                    <measurement group_id="O3" value="-0.402" spread="2.8000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin</title>
        <description>The change in adiponectin collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin</title>
          <description>The change in adiponectin collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>Âµg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 5 minutes prior to meal (n=24;n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.0004"/>
                    <measurement group_id="O2" value="0.000" spread="0.0005"/>
                    <measurement group_id="O3" value="0.006" spread="0.0005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24;n=25;n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0005"/>
                    <measurement group_id="O2" value="0.000" spread="0.0005"/>
                    <measurement group_id="O3" value="0.007" spread="0.0005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)</title>
        <description>The change in VCAM collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)</title>
          <description>The change in VCAM collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 5 minutes prior to meal (n=24;n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.351" spread="17.6828"/>
                    <measurement group_id="O2" value="2.392" spread="18.8767"/>
                    <measurement group_id="O3" value="4.849" spread="19.8297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24;n=25;n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.067" spread="16.6654"/>
                    <measurement group_id="O2" value="-1.441" spread="16.3094"/>
                    <measurement group_id="O3" value="13.665" spread="17.7580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)</title>
        <description>The change in ICAM collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)</title>
          <description>The change in ICAM collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 5 minutes prior to meal (n=24;n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.154" spread="6.7415"/>
                    <measurement group_id="O2" value="-0.294" spread="7.1785"/>
                    <measurement group_id="O3" value="-23.810" spread="7.6380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24; n=25;n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.495" spread="8.6653"/>
                    <measurement group_id="O2" value="-4.140" spread="8.4752"/>
                    <measurement group_id="O3" value="-16.556" spread="9.3414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in e-Selectin</title>
        <description>The change in e-Selectin collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline, Week 4 and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in e-Selectin</title>
          <description>The change in e-Selectin collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: 5 minutes prior to meal (n=24;n=21; n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.041" spread="1.3484"/>
                    <measurement group_id="O2" value="0.116" spread="1.4394"/>
                    <measurement group_id="O3" value="-6.437" spread="1.5137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 5 minutes prior to meal (n=24; n=25;n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.488" spread="2.0944"/>
                    <measurement group_id="O2" value="-1.671" spread="2.0480"/>
                    <measurement group_id="O3" value="-4.056" spread="2.2336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Endothelial Function Through Pulse Wave Tonometry</title>
        <description>Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment.</description>
        <time_frame>Baseline and Week 16.</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Endothelial Function Through Pulse Wave Tonometry</title>
          <description>Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Participants who were in the full analysis set and had a baseline and at least 1 post-baseline assessment were included for this analysis. Missing values were imputed using last observation carried forward.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16: pre-meal (n=23;n=23;n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="2.51"/>
                    <measurement group_id="O2" value="-4.7" spread="2.52"/>
                    <measurement group_id="O3" value="-4.2" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 2 hours postmeal (n=24;n=24;n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.16"/>
                    <measurement group_id="O2" value="0.1" spread="3.18"/>
                    <measurement group_id="O3" value="-1.3" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days after the last dose of double-blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory values or ECG findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo QD</title>
          <description>Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Alogliptin 25 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Alogliptin 25 mg QD + Pioglitazone 30 mg QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

